Publications by authors named "L Fenwarth"
Article Synopsis
- Despite initial treatment with midostaurin (MIDO) and chemotherapy in FLT3-mutated acute myeloid leukemia (AML), many patients face relapses, with complete remission rates around 60-70% and over 40% relapsing.
- A study of 150 patients with refractory/relapsed (R/R) AML revealed that those treated with MIDO showed lower persistence of FLT3-ITD mutations compared to those who did not receive MIDO (68% vs. 87.5%).
- The study found that detecting multiple FLT3-ITD clones at diagnosis related to a higher persistence rate of these mutations at relapse, indicating the need for sensitive techniques in FLT3-
Article Synopsis
- Acute myeloid leukemia (AML) often involves deletions of chromosome 7, which are linked to poor patient outcomes, but the full impact of other genetic changes related to this is not well understood.
- Researchers analyzed genetic alterations in 519 AML patients, using whole-exome sequencing and a specialized gene panel, finding that mutations in TP53, which occurred in 33% of cases, were among the most common.
- The study identified specific genes, like TP53 and PTPN11, that have a significant negative effect on overall and relapse-free survival, highlighting the complex relationship between chromosome 7 abnormalities and patient prognosis in AML.
Background: Lenalidomide is the standard of care for patients who are transfusion dependent with chromosome 5q deletion (del[5q]) myelodysplastic syndromes. In the SintraREV trial, we aimed to investigate whether an early intervention of low lenalidomide doses for 2 years could delay transfusion dependency in patients with anaemia who were not transfusion dependent.
Methods: This randomised, double-blind, phase 3 trial, was conducted at 22 sites (University Hospitals) in Spain, France, and Germany.